Literature DB >> 28001289

Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children With Relapsed or Refractory Pediatric Sarcomas.

J Carter1, L Cheng2, J Zucker1, M Marshall3, K Pollok1, M Murray3, L Li2, J Renbarger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28001289      PMCID： PMC5511378          DOI： 10.1002/cpt.599

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  1 in total

1.  Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Authors:  Milan Radovich; Patrick J Kiel; Stacy M Nance; Erin E Niland; Megan E Parsley; Meagan E Ferguson; Guanglong Jiang; Natraj R Ammakkanavar; Lawrence H Einhorn; Liang Cheng; Mehdi Nassiri; Darrell D Davidson; Daniel A Rushing; Patrick J Loehrer; Roberto Pili; Nasser Hanna; J Thomas Callaghan; Todd C Skaar; Paul R Helft; Safi Shahda; Bert H O'Neil; Bryan P Schneider
Journal:  Oncotarget       Date:  2016-08-30
  1 in total
  1 in total

Review 1.  Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas.

Authors:  Farinaz Barghi; Harlan E Shannon; M Reza Saadatzadeh; Barbara J Bailey; Niknam Riyahi; Khadijeh Bijangi-Vishehsaraei; Marissa Just; Michael J Ferguson; Pankita H Pandya; Karen E Pollok
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.